MedPage Today on MSN

PD-1 Inhibitor Raises PFS in Advanced Acral Melanoma

First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but ...
Yahoo

ESMO 2025: Hutchmed’s VEGF plus Innovent’s PD-1 inhibitor bolsters PFS in RCC

Hutchmed's fruquintinib and Eli Lilly & Innovent Biologics' Tyvyt (sintilimab) significantly improved PFS during a Phase III trial in second-line renal cell carcinoma (RSS). Image credit: Kateryna Kon ...
Forbes

A Deeper Look at Anti-PD-1/PD-L1 Checkpoint Inhibitors for Cancer

When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...
Forbes

Another Approach To Checkpoint Inhibitors: Targeting Receptors

Checkpoint inhibitors are antibody-based cancer therapies that unlock the immune system’s natural ability to fight cancer. These treatments work by blocking special proteins called immune checkpoints, ...
News Medical

PD-1 deficiency reveals the impact of checkpoint inhibition on B cell function

A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint ...
Business Wire

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has entered into a collaboration and supply agreement with BeiGene, Ltd. (to be changed to BeOne Medicines, ...